The clinical potential of Deprenyl in neurologic and psychiatric disorders

Journal of Neural Transmission, Supplement

Volumn , Issue 48, 1996, Pages 85-93

  Kuhn, W ^a   Muller Th ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SELEGILINE; ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; GILLES DE LA TOURETTE SYNDROME; HUMAN; MENTAL DISEASE; NARCOLEPSY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; ADULT; AGED; CHILD; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; TREATMENT OUTCOME;

ADULT; AGED; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHILD; CLINICAL TRIALS; CROSS-OVER STUDIES; DEPRESSION; DOUBLE-BLIND METHOD; HUMANS; MENTAL DISORDERS; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; NARCOLEPSY; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PARKINSON DISEASE, SECONDARY; SCHIZOPHRENIA; SELEGILINE; SUPRANUCLEAR PALSY, PROGRESSIVE; TOURETTE SYNDROME; TREATMENT OUTCOME;

EID: 0030300165     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-7494-4_8     Document Type: Review

References (23)

1. Agid Y, Javoy-Agid F, Ruberg M, et al (1986) Progressive supranuclear palsy: anatomoclinical and biochemical considerations. Adv Neurol 45: 191-206
2. Agnoli A, Martucci N, Fabbrini G, et al (1990) Monoamine oxidase and dementia: treatment with an inhibitor of MAO-B activity. Dementia 1: 109-114
3. Baldessarini RJ (1979) Neurological toxicology of antipyschotic drugs. McLean Hosp J 4: 2-19
4. Bamford CR, Montgomery EB jr, Munoz JE, et al (1993) Postpolio syndrome-response to deprenyl (selegiline). Int J Neurosci 71(1-4): 183-188
5. Bucci L (1987) The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology 91: 104-108
6. Burke WJ, Roccaforte WH, Wengel SP, et al (1993) L-Deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 41(11): 1219-225
7. Campi N, Todeschini GP, Scarzella L (1990) Selegiline versus L-acetylcarnitine in the treatment of Alzheimer type dementia. Clin Ther 12: 306-314
8. Chouinard G, Jones BD, Annable L (1980) L-dopa in neuroleptic induced extrapyramidal symptoms. 35th Annual Convention of Society of Biological Psychiatry of USA, Boston
9. Cohen G, Spina MB (1989) Deprenyl suppresses the oxidant stress associated with increased dopamine turn-over. Ann Neurol 26: 689-690
10. Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process? Br Med J 280: 66-68
11. Gewirtz GR, Sharif Z, Cadet JL, Sarti P, Gorman JM (1993) Selegiline for neuroleptic-induced Parkinsonism. Pharmacopsychiat 26: 128-129
12. Goff DC, Renshaw PF, Sarid-Segal O, et al (1993) A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry 33: 700-706
13. Heinonen EH, Lammintausta R (1991) A review of the pharmacology of selegiline. Acta Neurol Scand 136 [Suppl]: 44-59
14. Hublin C, Partinen M, Heinonen EH, Punkka P, Salmi T (1994) Selegiline in the treatment of narcolepsy. Neurology 44: 2095-2101
15. Jankovic J (1992) Diagnosis and classification of tics and Tourette Syndrome. Adv Neurol 58: 7-14
16. Jankovic J (1993) Deprenyl in attention deficit associated with Tourette's syndrome. Arch Neurol 50: 286-288
17. Jossan SS, Ekblom J, Gudjonsson O, Hagbarth KE (1994) Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis. J Neural Transm [Suppl] 41: 237-241
18. Knoll J (1989) The pharmacology of selegiline ((-)deprenyl). New aspects. Acta Neurol Scand 126 [Suppl]: 83-91
19. Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. In: Costa E, Sandler M (eds) Monoamine oxidase - new vistas. Raven Press, New York, pp 393-408
20. Kuritzky A, Zoldan Y, Melamed E (1992) Selegiline, a MAO-B inhibitor, is not effective in the prophylaxis of migraine without aura - an open study. Headache 32(8): 416
21. Lavie P, Wajsbort J, Youdim MBH (1980) Deprenyl does not cause insomnia in parkinsonian patients. Commun Psychopharmacol 4: 303-307
22. Lohr JB (1991) Oxygen radicals and neuropsychiatric illness. Arch Gen Pschiatry 48: 1097-1106
23. Mangoni A, Grassi MP, Frattola L, Piolti R, Bassi S, Motta A, Marcone A, Smirne S (1991) Effects of a MAO-B inhibitor in the treatment of Alzheimer's disease. Eur Neurol 31: 100-107